Abstract 86P
Background
TOPAZ-1 (NCT03875235) is a double-blind, Phase 3 study of durvalumab (D) + gemcitabine and cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC). D + GemCis improved overall survival (OS) vs placebo (PBO) + GemCis, and is a potential new treatment option (Oh et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2200015). In BTC, primary tumour location may impact risk factors, prognoses and treatment response.
Methods
This exploratory subgroup analysis of TOPAZ-1 assessed efficacy outcomes by primary tumour location (intrahepatic [IHCC], extrahepatic [EHCC] cholangiocarcinoma or gall bladder cancer [GBC]). Pts were randomised 1:1 to receive D (1500 mg) or PBO on Day 1 Q3W, + Gem (1000 mg/m2) and Cis (25 mg/m2) on Day 1 and 8 Q3W, for ≤8 cycles, followed by D or PBO monotherapy until disease progression, unacceptable toxicity or discontinuation. Randomisation was stratified by disease status (initially unresectable vs recurrent) and primary tumour location (IHCC vs EHCC vs GBC).
Results
Patient numbers with IHCC, EHCC and GBC were balanced between treatment arms; more pts had IHCC than EHCC or GBC (Table). Efficacy outcomes by primary tumour location are summarised (Table). To aid in understanding the higher hazard ratio (HR) in GBC, regional analysis was performed: OS HR for GBC in Asia was 0.82 (95% confidence interval [CI], 0.48-1.40) and in Europe plus North America (non-Asian countries minus South America) was 0.78 (95% CI, 0.44-1.37) Table: 86P
Efficacy outcomes by primary tumour location (RECIST v1.1)
Primary tumour location | Group (n) | Overall survival, HR (95% CI)∗ | Progression-free survival, HR (95% CI)∗ | Objective response rate | Responders with duration of response ≥9/12 months, % | |
% | Odds ratio (95% CI)† | |||||
Intrahepatic cholangiocarcinoma | D + GemCis (n=190) | 0.76 (0.58–0.98) | 0.79 (0.64–0.99) | 24.7 | 1.79 (1.07–2.97) | 28.3/18.9 |
PBO + GemCis (n=193) | 15.5 | 24.0/12.0 | ||||
Extrahepatic cholangiocarcinoma | D + GemCis (n=66) | 0.76 (0.49–1.19) | 0.52 (0.35–0.78) | 28.8 | 2.18 (0.92–5.16) | 43.3/43.3 |
PBO + GemCis (n=65) | 15.6 | 23.3/23/3 | ||||
Gallbladder cancer | D + GemCis (n=85) | 0.94 (0.65–1.37) | 0.90 (0.65–1.24) | 29.4 | 1.08 (0.55–2.09) | 33.2/27.6 |
PBO + GemCis (n=86) | 27.9 | 27.5/16.5 |
∗Calculated using a Cox proportional hazards model.†Calculated using the Cochran-Mantel Haenszel test.
.Conclusions
D + GemCis appeared to improve efficacy outcomes (not formally tested for subgroup comparisons) for pts with IHCC, EHCC and GBC. Findings support D + GemCis as a potential new treatment option for advanced BTC, irrespective of primary tumour location.
Clinical trial identification
NCT03875235.
Editorial acknowledgement
Medical writing support, under the direction of the authors, was provided by Elaine Groat, PhD, of CMC Connect, McCann Health Medical Communications, with funding from AstraZeneca, in accordance with Good Publication Practice (GPP3) guidelines.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
A.R. He: Financial Interests, Personal, Other, Advisory Board meeting on management of biliary cancer and HCC: AstraZeneca. J.W. Valle: Financial Interests, Personal, Advisory Board: Astra-Zeneca, Agios, QED, NuCana BioMed, Servier, Image Equipment Ltd. (AAA), Hutchinson Medipharma, Zymeworks, Sirtex, Baxter, Autem, Hutchinson Medipharma; Financial Interests, Personal, Invited Speaker: Ipsen, Mylan, Incyte; Financial Interests, Institutional, Research Grant, Grant funding for ABC-12 study: AstraZeneca; Financial Interests, Institutional, Research Grant, University of Manchester: RedX. M. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, Ono, Takeda, GlaxoSmithKline; Financial Interests, Personal, Invited Speaker: AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, Taiho, Yakult, Teijin Pharma, AbbVie, Abbott Japan, Fujifilm Toyama Chemical, Incyte Biosciences Japan, ASLAN, Chugai, NIHON SERVIER, Takeda; Financial Interests, Institutional, Invited Speaker: Bayer, Bristol Myers Squibb, Eisai, AstraZeneca, Eli Lilly Japan, Chugai Pharmaceutical, Merck Serono, MSD, Ono, Yakult, Novartis, Takeda, J-Pharma, Pfizer, Chiome Bioscience, NIHON Servier, Delta-Fly Pharma, Syneos Health, Merus.N.V. P. Potemski: Financial Interests, Personal, Other, Principal investigator Invited speaker Advisory Board: AstraZeneca; Financial Interests, Personal, Other, Principal investigator Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Ipsen, Merck; Financial Interests, Personal, Other, Invited speaker Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD. C. Morizane: Financial Interests, Personal, Advisory Board: Yakult, MSD, Servier, Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, Merck biopharma; Financial Interests, Personal, Invited Speaker: Novartis, Teijin Pharma; Financial Interests, Institutional, Invited Speaker: Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, Eisai, MSD K.K., J-Pharma, AstraZeneca, Merck Biopharma; Financial Interests, Institutional, Funding: Daiichi Sankyo RD Novare, Hitachi. J.E. Cundom: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Boheringer Ingelheim, Astra Zeneca, Takeda, Roche. D. Tougeron: Financial Interests, Personal, Advisory Board: AstraZeneca, Sanofi, Amgen, MSD, Roche, Servier, Servier, Pierre Fabre. F. Dayyani: Financial Interests, Personal, Other, Consulting fees: AstraZeneca, Natera, Exelixis, Genentech; Financial Interests, Personal, Speaker’s Bureau: Deciphera, Eisai, Exelixis, Ipsen, Servier, Natera, Sirtex; Financial Interests, Personal, Other, Contracted research: AstraZeneca, BMS, Taiho, Exelixis, Merck, Trishula, Natera, Ipsen. N. Rokutanda: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. J. Xiong: Financial Interests, Personal, Other, Former employee: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. G. Cohen: Financial Interests, Personal, Full or part-time Employment, I am a full time employee of AstraZeneca. Position is Global Clinical Lead in Immuno-oncology: AstraZeneca; Financial Interests, Personal, Stocks/Shares, Own stock in the company as an employee.: AstraZeneca. D. Oh: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA; Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, Handok. All other authors have declared no conflicts of interest.
Resources from the same session
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02